Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4603385 | 0.90 | CXCR2 (0.53) | FFAR1CXCR2LMNAL3MBTL1MAOB | |
| SCHEMBL4604985 | 0.88 | CXCR2 (0.54) | FFAR1CXCR2FFAR4LMNAL3MBTL1 | |
| SCHEMBL4618003 | 0.85 | CXCR2 (0.56) | CXCR2SRD5A2LMNAL3MBTL1PPARA | |
| SCHEMBL4633030 | 0.85 | CXCR2 (0.52) | FFAR1CXCR2FFAR4LMNAL3MBTL1 | |
| SCHEMBL4828979 | 0.85 | CXCR2 (0.57) | FFAR1CXCR2FFAR4LMNAL3MBTL1 | |
| SCHEMBL4602975 | 0.84 | CXCR2 (0.55) | CXCR2LMNAL3MBTL1PPARAMAOB | |
| SCHEMBL4605404 | 0.84 | PPARA (0.48) | CXCR2LMNAPPARAMAOB | |
| SCHEMBL4604453 | 0.84 | CXCR2 (0.59) | CXCR2LMNAL3MBTL1PPARAMAOB | |
| SCHEMBL4603993 | 0.84 | SENP5 (0.47) | CXCR2LMNAMAOB | |
| SCHEMBL4603929 | 0.83 | PPARA (0.53) | CXCR2LMNAPPARAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685122-B1 | BENZOFURANS AND BENZOTHIOPHENES | MERCK PATENT GMBH (DE) | 2008-07-09 | — | — | EP | claimed |
| EP-1685122-B1 | BENZOFURANS AND BENZOTHIOPHENES | MERCK PATENT GMBH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-7371774-B2 | Benzofurans and benzothiophenes | MERCK PATENT GMBH (DE) | 2008-05-13 | — | — | US | disclosed |
| US-20070066680-A1 | Benzofurans and benzothiophenes | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066680-A1 | Benzofurans and benzothiophenes | INSR, GPR119, IGF1R | FFAR1 246/4885CXCR2 1633/4885SRD5A2 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.